Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Korea Accelerating Efforts To Develop, Launch Orphan Drugs

This article was originally published in SRA

Executive Summary

South Korea's Ministry of Food and Drug Safety has issued revised rules to ease the designation and approval of orphan drugs. The changes are expected to create an environment that would support aggressive development of orphan drugs by the domestic pharmaceutical industry and result in more treatment options for patients.

You may also be interested in...



Korea Lowers Medical Cost For Rare Disease Patients, Eases Off-Label Use Rules

In an ongoing effort to improve access to drugs and provide more treatment options for rare disease patients, South Korea unveils new steps to lower their treatment costs and expand the scope of what are considered rare diseases.

Pfizer’s Goettler On What Partners Look For In Orphan Drug Deals

Michael Goettler, Pfizer's global president, rare disease global innovative pharma business, offers tips to Korean orphan drug developers on reaching out to potential partners successfully and what Pfizer is looking for in rare disease deals.

2016 Review: Despite Political Woes, Korea Pro-Pharma Policies Stay Intact

2016 has been full of shock and despair in South Korea’s political scene. But when it comes to the country’s biopharma policy, the year has seen fewer surprising or dramatic events.

UsernamePublicRestriction

Register

SC081785

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel